0.06 (-%)
As of May 18, 2023
Source:
We are a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel, proprietary, synthetic small molecules for the treatment of brain and nervous system disorders. We focus our efforts on targeting and modulating N-methyl-D-aspartate receptors, or NMDArs, which are vital to normal and effective function of the brain and nervous system. We believe leveraging the therapeutic advantages of the differentiated modulatory mechanism of our compounds will drive a paradigm shift in the treatment of disorders of the brain and nervous system.
Country | United States |
Headquarters | evanston, illinois |
Phone Number | 847-871-0377 |
Industry | manufacturing |
CEO | Andrew Kidd |
Website | www.aptinyx.com |